ArticleEuropean journal of medical research2026
lncRNA SND1-IT1/miR-494-3p regulation in ox-LDL-induced endothelial cell injury: novel insights into coronary heart disease pathogenesis and diagnostic biomarkers.
Article in European journal of medical research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesCoronary heart disease (CHD) is a major challenge in cardiovascular disease. This study investigated the role of lncRNA SND1-IT1 in oxidized low-density lipoprotein (ox-LDL)-induced injury of human umbilical vein endothelial cells (HUVECs). MATERIALS AND
methodsSerum was collected from healthy individuals and CHD patients. SND1-IT1 and miR-494-3p expression was analyzed by RT-qPCR, with ROC curves evaluating diagnostic potential. HUVECs were exposed to ox-LDL to induce injury and transfected to modulate target molecule expression. Cell viability and apoptosis were assessed using CCK8 and flow cytometry. Inflammatory cytokines and antioxidant enzymes were assessed by ELISA. Molecular interactions were verified through dual-luciferase reporters and RIP.
resultsIn CHD patients, SND1-IT1 expression was significantly elevated (1.29 ± 0.18) compared to healthy controls (1.00 ± 0.14, P < 0.001), while miR-494-3p expression was notably downregulated (0.72 ± 0.16 vs. 1.01 ± 0.15, P < 0.001). Their combined assessment provide effective diagnostic value for CHD occurrence. Ox-LDL damaged HUVECs by inhibiting viability, enhancing apoptosis, inflammation, oxidative stress, and cell adhesion. SND1-IT1 knockdown alleviated these ox-LDL-induced injuries. SND1-IT1 acts as a sponge for miR-494-3p, whose downregulation reversed the protective effects of SND1-IT1 silencing. ZBTB20 was identified as a direct target of miR-494-3p and was upregulated in ox-LDL-treated HUVECs, counteracting the beneficial effects of miR-494-3p upregulation.
conclusionAltered SND1-IT1 and miR-494-3p expressions in CHD patients show potential as biomarkers for CHD risk assessment. SND1-IT1 may regulate ox-LDL-induced damage in HUVECs by modulating the interaction between miR-494-3p and ZBTB20.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.